

REMARKS

I. Status of Claims

Claims 1-25 and 28-31 are pending. Claim 29 has been cancelled without prejudice or disclaimer and the subject matter of claim 29, considered allowable, has been incorporated into claims 28 and 31. Claims 28 and 31 are amended without prejudice, to be directed to a method for treating asthma, atopic dermatitis and psoriasis. No new matter has been introduced by this amendment.

Applicants thank the Examiner for the allowance of claims 1-25 and 30.

II. Rejection under 35 U.S.C. § 112

The Examiner rejected claims 28, 29 and 31 under 35 U.S.C. § 112, first paragraph as failing to comply with the enablement requirement. Office Action at 2. In particular, the Examiner contends that the specification "does not reasonably enable treatment of all pathological conditions/diseases susceptible to amelioration by phosphodiesterase 4 arthritis or irritable bowel disease." *Id.* The Examiner does concede that the specification is enabling for asthma, psoriasis and atopic dermatitis. See *id.*

Applicants respectfully traverse this rejection. However, in the interest of expediting prosecution, Applicants have cancelled claim 29 and amended claims 28 and 31 to be directed to subject matter considered enabled by the Office. Accordingly, the rejection is now moot and Applicants respectfully request that this rejection be withdrawn. Applicants reserve the right to pursue the cancelled subject matter in a continuation application.

III. Conclusion

After this amendment, Applicants believe all claims are in condition for allowance.

In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:



Carlos M. Tellez
Reg. No. 48,638

Dated: August 1, 2008